2015
Riboflavin‐ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells
Tormey CA, Santhanakrishnan M, Smith NH, Liu J, Marschner S, Goodrich RP, Hendrickson JE. Riboflavin‐ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells. Transfusion 2015, 56: 863-872. PMID: 26643781, DOI: 10.1111/trf.13432.Peer-Reviewed Original ResearchConceptsWhite blood cellsFresh whole bloodPathogen reduction treatmentAlloimmune responseWhole bloodRBC antigensSyngeneic RBCsNegative direct antiglobulin testBlood cellsRBC antigen expressionRecipient alloimmune responsesDirect antiglobulin testMurine red blood cellsPathogen inactivation treatmentPosttransfusion RBC recoveryKEL RBCsRBC alloimmunizationImmunogenic neoantigensRed blood cellsAntiglobulin testBlood donorsImmune responseAntigen expressionHours posttransfusionHuman antigens
2009
Clinical trials for pathogen reduction in transfusion medicine: A review
McClaskey J, Xu M, Snyder EL, Tormey CA. Clinical trials for pathogen reduction in transfusion medicine: A review. Transfusion And Apheresis Science 2009, 41: 217-225. PMID: 19793679, DOI: 10.1016/j.transci.2009.09.008.Peer-Reviewed Original ResearchMeSH KeywordsBlood TransfusionBlood-Borne PathogensClinical Trials as TopicDisinfectantsDisinfectionHumansInfection ControlTransfusion ReactionVirus InactivationConceptsClinical trialsBlood productsDonor screening programsDonor blood productsRisk of transmissionInfective donorsTransfusion recipientsScreening programClinical settingInfectious diseasesTransfusion medicineTesting regimensPI treatmentTrialsScreening assaysRiskPathogensPotential toxicityPromising strategyDetection of pathogensRegimensPathogen reductionSensitive methodDiseaseRecipients